Statute Details
- Title: Medicines (Labelling) Regulations
- Act Code: MA1975-RG5
- Legislative Type: Subsidiary legislation (sl)
- Authorising Act: Medicines Act (Cap. 176), section 44
- Regulation Citation: Rg 5
- Gazette / Instrument Reference: G.N. No. S 255/1986
- Revised Edition: Revised Edition 2000 (31st January 2000)
- Current Version Status: Current version as at 27 Mar 2026
- Key Definitions: “appropriate non-proprietary name”, “appropriate quantitative particulars”, “dispensed medicinal product”, “expiry date”, “international non-proprietary name”, “proprietary designation”, “specified publication”
- Key Provisions (extract): Regulation 3 (definitions), Regulation 3A (scope/exclusions), Regulation 4 (dispensed products—label particulars), Regulation 6 (certain substances—presence statement), Regulation 7 (date stamp—“Use by”/expiry), Regulation 8 (exceptions), Regulation 9 (label size/position/legibility)
- Notable Amendments (timeline): Amended by S 545/2016 (effective 1 Nov 2016); earlier amendments include S 525/1997, S 495/1998, and S 545/2016
What Is This Legislation About?
The Medicines (Labelling) Regulations set out mandatory requirements for how medicinal products must be labelled when they are sold, supplied, dispensed, or otherwise made available for human use in Singapore. In practical terms, the Regulations aim to ensure that patients, purchasers, and healthcare institutions can identify what a medicine is, who it is for (in the case of dispensed medicines), what directions apply, and—where relevant—what substances are present and when the product should no longer be used.
The Regulations operate as a consumer-protection and patient-safety framework within the broader Medicines Act regime. They do not attempt to regulate clinical use or prescribing decisions; instead, they focus on the information that must appear on labels and the physical presentation of that information (for example, font size, legibility, and placement). This is important because labelling is often the primary interface between a medicine and the end user.
Although the Regulations contain multiple categories of medicines, a central distinction runs through the text: dispensed medicinal products (typically supplied to a named patient by a doctor/dentist or dispensed by a registered pharmacist) are treated differently from medicines sold or supplied in circumstances corresponding to retail sale or wholesale dealing. The Regulations also carve out specific exclusions, including for Chinese proprietary medicines and clinical research material (as defined in related clinical research regulations).
What Are the Key Provisions?
1) Definitions and interpretive framework (Regulation 3)
The Regulations define key terms that drive compliance. For example, “appropriate non-proprietary name” is tied to recognised naming sources: it may be derived from a monograph in specified publications (European Pharmacopoeia, British Pharmacopoeia, US Pharmacopoeia National Formulary, Pharmaceutical Codex (British), or British National Formulary), or from an international non-proprietary name (INN) selected by the World Health Organisation, or otherwise from an accepted scientific/descriptive name. This matters because labelling obligations often require either the non-proprietary name or the proprietary designation.
Similarly, “appropriate quantitative particulars” requires disclosure of the quantity of each active ingredient in terms of weight, volume, capacity, units of activity, or—where there is no dosage unit—quantities in the container. These definitions ensure that “what must be shown” is not vague: the Regulations specify the type of ingredient-level information expected.
2) Scope and exclusions (Regulation 3A)
Regulation 3A provides that the Regulations do not apply to (a) Chinese proprietary medicines, and (b) any medicinal product (other than Chinese proprietary medicine) that is clinical research material as defined in the Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016. This is a critical practitioner point: if a product falls within these categories, the labelling requirements in these Regulations may not govern, and other regulatory instruments may apply instead.
3) Dispensed medicinal products—mandatory label particulars (Regulation 4)
Where a medicinal product is a “dispensed medicinal product”, the container must be labelled with specific particulars. The label must show: (a) the name of the person to whom the medicinal product is to be administered; (b) the name and address of the medical/dental practice, registered pharmacy, hospital, or other institution where it was supplied/dispensed, plus any identification number or mark; (c) the date of dispensing; (d) directions for use; (e) the name of the medicinal product, either the appropriate non-proprietary name or the proprietary designation; and (f) where the appropriate non-proprietary name is labelled, the appropriate quantitative particulars of the active ingredients.
This provision is particularly important for compliance audits in pharmacies and hospitals. It also affects how pharmacists and institutions structure their dispensing labels and what information must be captured at the time of dispensing. Practitioners should note that Regulation 4 is not merely about identifying the medicine; it also requires patient identification and dispensing provenance (who dispensed it and where), which supports traceability and safe administration.
4) Labelling for certain substances and expiry (“Use by”) (Regulations 6 and 7)
Regulation 6 applies when a medicinal product for human consumption or use contains any substance specified in the First Schedule, is not a dispensed medicinal product, and is sold by retail or supplied in circumstances corresponding to retail sale, or is possessed for such sale/supply. In that case, every container (and, where immediately enclosed, the package) must be labelled with a statement in English declaring the presence of that substance. The statement may use a corresponding term specified in the First Schedule or an equivalent term.
Regulation 7 addresses products containing substances specified in the Second Schedule (again, not dispensed medicinal products). For such products, every container and immediate package must be labelled with the words “Use by” (or similar words) followed by the expiry date. The expiry date requirement is subject to Regulation 8 exceptions.
5) Exceptions to expiry labelling (Regulation 8)
Regulation 7 does not apply to certain medicinal products, including: (a) products containing Ascorbic Acid (Vitamin C) or its salts sold as confectionery, provided they are not (and are not to be sold with) any particulars in writing specifying curative/remedial function, or use for disease specified on the container other than coughs, colds, or nasal congestion; and (b) products comprising wholly of substances specified in the Second Schedule that are sold/supplied by wholesale dealing mainly as ingredients for preparing another substance/article to be administered for medicinal purposes to humans or animals.
These exceptions are narrow and fact-sensitive. For example, the Vitamin C confectionery exception turns on whether the product is marketed with curative/remedial claims and whether disease-related particulars are included. Practitioners should therefore consider not only the ingredient composition but also the packaging claims and accompanying written materials.
6) Label format, size, position, and legibility (Regulation 9)
Regulation 9 sets out physical labelling standards. All particulars required by the Regulations must be printed in letters not less than 1.5 millimetres in height, clearly legible, and conspicuously displayed in a prominent position so they are easily read by an intending purchaser or user under normal conditions of purchase or use. Where the container or package is too small to accommodate the specified size, the statement may be printed in reduced size, provided it remains clearly legible.
Regulation 9 also contains practical rules for blister packs and continuous series of sealed units. Where containers are part of a sheet or strip, compliance may be achieved if the required particulars are displayed at frequent intervals on the sheet/strip. Similar logic applies where the immediate enclosing package is itself a sealed unit in a continuous series. These provisions are highly relevant to manufacturers and packers who must design labels that work across different packaging formats.
How Is This Legislation Structured?
The Regulations are structured as a set of numbered regulations with definitional and scope provisions at the front, followed by substantive labelling obligations and technical presentation requirements. Based on the extract and the listed provisions, the structure includes:
Regulation 1 (Citation); Regulation 2 (Deleted in the current version); Regulation 3 (Definitions); Regulation 3A (Scope/exclusions); Regulation 4 (Particulars on labels for dispensed medicinal products); Regulation 5 (Deleted); Regulation 6 (Labelling of certain substances—presence statement); Regulation 7 (Products to carry date stamp—“Use by”/expiry); Regulation 8 (Exceptions to Regulation 7); Regulation 9 (Label dimensions, position, and legibility); and two schedules (First Schedule and Second Schedule) that list substances triggering the additional labelling requirements.
For practitioners, the schedules are not optional: they determine which substances trigger the presence statement (First Schedule) and which trigger the “Use by” expiry labelling (Second Schedule). Even where the main text is familiar, compliance depends on correctly mapping the product’s ingredients to the schedules.
Who Does This Legislation Apply To?
The Regulations apply to parties involved in the supply chain of medicinal products in Singapore—particularly those responsible for labelling at the point of sale or supply. Regulation 4 targets dispensed medicinal products, which are dispensed by doctors/dentists to patients or by pharmacists in registered retail pharmacy premises. Regulations 6 and 7 target medicines that are not dispensed medicinal products and are sold by retail, supplied in circumstances corresponding to retail sale, or possessed for such sale/supply. Regulation 7 also expressly covers wholesale dealing.
In addition, the Regulations apply to manufacturers, packers, importers, and distributors insofar as they must ensure that containers and packages carry the required particulars and meet the technical labelling standards. However, the scope is limited by Regulation 3A: Chinese proprietary medicines and clinical research material (as defined in the 2016 clinical research regulations) are excluded from these labelling requirements.
Why Is This Legislation Important?
Medicines labelling is a high-risk compliance area because errors can lead to patient harm, misuse, or inability to identify a medicine correctly. The Regulations provide a clear baseline of required information, including patient identification and dispensing provenance for dispensed products (Regulation 4), and ingredient/substance disclosure and expiry labelling for other medicinal products (Regulations 6 and 7). This supports both safe use and regulatory traceability.
From an enforcement and risk-management perspective, the Regulations also create objective standards. For example, Regulation 9’s minimum font size and conspicuous placement requirements allow regulators and auditors to assess compliance without relying solely on subjective impressions. Similarly, the “Use by” requirement provides a clear textual marker tied to an expiry date, reducing ambiguity.
For practitioners advising healthcare providers or pharmaceutical businesses, the most practical value of these Regulations lies in their mapping logic: determine whether the product is a “dispensed medicinal product”; if not, check whether it contains substances listed in the First or Second Schedule; then apply the corresponding labelling requirements and exceptions. Finally, ensure that the label design meets the technical legibility and packaging-format rules, including blister packs and continuous series.
Related Legislation
- Medicines Act (Cap. 176), section 44 (authorising provision)
- Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016 (definition of clinical research material used in Regulation 3A)
- Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order (definition of “Chinese proprietary medicines” referenced in Regulation 3)
Source Documents
This article provides an overview of the Medicines (Labelling) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.